Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 7,248 matching trials from the live ClinicalTrials.gov search.

Filters: Detroit, Michigan Clear all

Conditions: Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Interventions: Capecitabine, Carboplatin, Cisplatin; Drug
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2031
U.S. locations: 1023
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 634 more

Conditions: Epilepsy
Interventions: E2007 (perampanel), Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 70 Years
Timeline: 2005 – 2007
U.S. locations: 5
States / cities: Little Rock, Arkansas • Tampa, Florida • Detroit, Michigan + 2 more

Conditions: Autistic Disorder, Behavioral Symptoms
Interventions: Aripiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 55
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 49 more

Conditions: Peripheral T-cell Lymphoma
Interventions: Pralatrexate Injection; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 3
States / cities: Novi, Michigan • New York, New York

Conditions: Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions: Biospecimen Collection, Carboplatin, Computed Tomography, Ipilimumab, Nivolumab, Paclitaxel, Positron Emission Tomography, Radiation Therapy; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 488
States / cities: Anchorage, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 341 more

Conditions: Solid Tumor
Interventions: SAR302503, omeprazol, metoprolol, midazolam; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Augusta, Georgia • Detroit, Michigan • Philadelphia, Pennsylvania

Conditions: Asthma
Interventions: FP 100mcg, FSC 100/50mcg, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 908 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 141
States / cities: Ozark, Alabama • Tucson, Arizona • Little Rock, Arkansas + 118 more

Conditions: Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)
Interventions: Dersimelagon, Placebo; Drug
Lead sponsor: Tanabe Pharma America, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 13
States / cities: Huntington Beach, California • San Francisco, California • Miami, Florida + 10 more

Conditions: Heart Failure, Congestive
Interventions: Eplerenone; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 53
States / cities: Castro Valley, California • San Diego, California • Santa Rosa, California + 42 more

Conditions: Hemophilia A
Interventions: Bypassing Agents, FVIII Replacement; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Not listed
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 10
States / cities: Santa Monica, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more

Conditions: Breast Cancer; HER2-positive; Metastatic
Interventions: Trastuzumab deruxtecan, Placebo, Taxane, Pertuzumab, Trastuzumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 30
States / cities: Tucson, Arizona • Springdale, Arkansas • Glendale, California + 25 more

Conditions: Chronic Graft Versus Host Disease
Interventions: ECP Methoxsalen, Standard of Care; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 11
States / cities: Miami, Florida • Indianapolis, Indiana • New Orleans, Louisiana + 7 more

Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Interventions: Renal Denervation (Symplicity Spyral™); Device
Lead sponsor: Medtronic Vascular; Industry
Eligibility: 18 Years and older
Enrollment: 1,899 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 76
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 67 more

Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Interventions: Pegozafermin, Placebo; Biological · Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 150
States / cities: Birmingham, Alabama • Homewood, Alabama • Chandler, Arizona + 123 more

Conditions: Dermatitis, Atopic
Interventions: PF-04965842 100 mg, PF-04965842 200 mg, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 29
States / cities: Birmingham, Alabama • Encinitas, California • San Diego, California + 21 more

Conditions: Septic Shock, Sepsis, Hypovolemia
Interventions: VBI-S; Drug
Lead sponsor: Vivacelle Bio; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 8
States / cities: Chandler, Arizona • Tucson, Arizona • Baltimore, Maryland + 5 more

Conditions: Chronic Obstructive Pulmonary Disease, Exacerbation of Chronic Obstructive Pulmonary Disease
Interventions: Bundle tool; Behavioral
Lead sponsor: Henry Ford Health System; Other
Eligibility: 40 Years to 99 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Malignant Solid Tumor
Interventions: ZL-1218, Pembrolizumab; Drug
Lead sponsor: Zai Lab (Hong Kong), Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 5
States / cities: Irvine, California • Detroit, Michigan • Hackensack, New Jersey + 2 more

Conditions: Malignant Melanoma
Interventions: DEDN6526A; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 4
States / cities: Los Angeles, California • Sarasota, Florida • Detroit, Michigan + 1 more

Conditions: Myelodysplastic Syndrome
Interventions: vadastuximab talirine, Azacitidine, Placebo (for 33A); Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 34
States / cities: Gilbert, Arizona • Los Angeles, California • Aurora, Colorado + 29 more

Conditions: Hepatitis C, Chronic
Interventions: Copegus, Danoprevir, Pegasys, Ritonavir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 25
States / cities: La Jolla, California • Sacramento, California • San Diego, California + 20 more

Conditions: Acne Vulgaris
Interventions: Sarecycline, Placebo; Drug
Lead sponsor: Almirall, S.A.; Industry
Eligibility: 9 Years to 45 Years
Enrollment: 968 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 57
States / cities: Beverly Hills, California • Encino, California • La Mesa, California + 50 more

Conditions: Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization, Healthy Volunteers
Interventions: RSV+HMPV vaccine, Control Vaccine 3, Control Vaccine 4, Control Vaccine 2, Placebo, Control Vaccine 1; Biological · Other
Lead sponsor: Sanofi; Industry
Eligibility: 60 Years and older
Enrollment: 2,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 50
States / cities: Gadsden, Alabama • Vestavia Hills, Alabama • Huntington Beach, California + 43 more

Conditions: Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer, Squamous Cell Carcinoma of Head and Neck
Interventions: BIND-014 (docetaxel nanoparticles for injectable suspension); Drug
Lead sponsor: BIND Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 8
States / cities: Goodyear, Arizona • Greenbrae, California • Denver, Colorado + 5 more

Search by objective public record fields.

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)

Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients

Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery

Drug Interaction Study of SAR302503 in Patients With Solid Tumor

Advair Pediatric Once-Daily

INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP

The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure

A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)

SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

VBI-S for the Treatment of Hypotension in Hypovolemic Septic Shock Patients

Pre-Discharge Bundle for Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease to Reduce Readmissions

A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors

A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma

Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection

Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne

Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older

A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck